Introduction
============

Hemostatic factors play important roles in cancer development, growth, and metastasis. Plasma fibrinogen is an acute phase glycoprotein associated with hemostasis maintenance and is a key factor in inflammation [@B1]. Fibrinogen is reportedly synthesized and overexpressed in human tumors [@B2], and plays an important role in tumor cell proliferation, invasion, and angiogenesis [@B3], [@B4]. Pretreatment fibrinogen levels can predict survival outcomes in various urological cancers, including renal cell carcinoma (RCC) [@B5], [@B6], prostate cancer (PCa) [@B7], upper tract urothelial carcinoma (UTUC) [@B8], and others [@B9]. However, the prognostic role of fibrinogen is still unclear. Du, *et al.* and Lee, *et al.* showed that high preoperative plasma fibrinogen levels predicted worse overall survival (OS) in RCC patients [@B6] [@B10], while Erdem, *et al.* found no relationship between plasma fibrinogen levels and OS in localized RCC patients [@B11]. Perisanidis, *et al.* performed a meta-analysis in solid tumors to assess the prognostic value of pretreatment fibrinogen, but their study focused on RCC and included only a small number of studies [@B12]. Another recent meta-analysis focused on the association between fibrinogen and RCC[@B13], PCa and UTUC were still not taken into account. Thus, the present meta-analysis included more cancer types and additional recent studies in evaluating the prognostic value of pretreatment plasma fibrinogen on survival outcomes in urological cancers.

Materials and Methods
=====================

Before starting our research, we registered our systematic review project at PROSPERO (International Prospective Register of Systemic Reviews, <http://www.crd.york.ac.uk/prospero>; registration code: CRD42016043821). We conducted this meta-analysis according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) criteria ([Supplementary Material](#SM0){ref-type="supplementary-material"}).

Literature search
-----------------

We systematically searched PubMed and Embase to obtain all eligible clinical studies published before May 2017. There was no language restriction in our search. We used Mesh terms and keywords (fibrinogen, renal cell carcinoma, upper tract urothelial carcinoma, bladder cancer, prostate cancer, and urological cancer) to search for related articles in the databases ([Supplementary Material](#SM0){ref-type="supplementary-material"}). We also examined the references of relevant articles to retrieve potentially eligible studies. Two investigators (Haifeng Song and Guanyu Kuang) independently conducted the literature search.

Inclusion and exclusion criteria
--------------------------------

Studies were included if they met all of the following criteria: 1) cohort studies on patients with urological tumors who were diagnosed pathologically; 2) survival outcomes included overall survival (OS) and/or cancer-specific survival (CSS); 3) results were expressed as hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) or P-values, or HRs could be calculated based on information provided in the article. Studies were excluded based on any of the following criteria: 1) review articles, case reports, laboratory articles, or letters; 2) papers lacked key information to calculate HRs; 3) if more than one study used the same patient cohort, only the most recent or complete study was selected.

Data extraction and quality assessment
--------------------------------------

Two reviewers independently extracted data from all eligible studies using a predesigned form. Extracted data included first author name, publication year, country, tumor site, sample size, patient age and gender, cut-off value, follow-up duration, outcome measures (OS, CSS, HRs, 95%CI), and survival analysis (univariate/multivariate). If both univariate and multivariate analyses were conducted, we chose the multivariate analysis HRs, which accounted for confounding factors. We assessed study quality according to the Newcastle-Ottawa Scale (NOS). NOS includes three domains with eight items. Each item was awarded one or two stars. Studies with more than five stars were deemed good quality. Data extractions and quality assessments were performed independently by two investigators (Haifeng Song and Guanyu Kuang). Disagreements were resolved by a third reviewer (Binglei Ma) and group discussion.

Statistical analysis
--------------------

The prognostic values of plasma fibrinogen levels in urological cancers were evaluated using HRs and 95% CIs of CSS and OS, which we extracted directly from original articles. Cochran\'s Q-test and Higgins I^2^ statistics (I^2^) were used to evaluate the heterogeneity of included studies. Heterogeneity was indicated by I^2^\>50% or P\<0.05. The fixed-effects model (Mantel-Haenszel method) was used to calculate pooled HRs if there was no heterogeneity. Otherwise, the random effect model was used. Subgroup analysis was conducted to identify the source of heterogeneity. Egger\'s and Begg\'s tests were performed to evaluate publication bias. All statistical analyses were performed using STATA version 14.0 (Stata Corporation, College Station, TX, USA).

Results
=======

Characteristics of included studies
-----------------------------------

We identified 879 records by searching the PubMed and Embase databases. Two records were identified by examining article bibliographies. We excluded 96 duplicates. After screening titles and abstracts, 763 records were excluded and the remaining 22 were selected for full-text reading. Eight of these 22 articles were excluded: two studies were not prognosis-related, four had no OS or CSS as final outcome, and two included data that overlapped with other studies. In total, 14 studies met our eligibility criteria and were included in the final meta-analysis (Fig [1](#F1){ref-type="fig"}, Table [1](#T1){ref-type="table"}).

The included studies had 6740 total cases from six countries (China, Japan, Korea, Germany, Austria, and Turkey). Two studies explored the prognostic value of fibrinogen in PCa (including 558 patients), eight in RCC (including 5132 patients), and four in UTUC (including 1050 patients). There were no studies of bladder cancer. As for survival outcomes, 11 studies evaluated the prognostic value of fibrinogen in predicting OS, and 12 evaluated CSS. All included studies had NOS scores \>5 and were considered good quality.

Overall survival
----------------

High pretreatment plasma fibrinogen level was associated with worse OS in urological cancers (fixed effect model, pooled HR=2.21, 95% CI=1.91-2.57; P\<0.001) (Fig [2](#F2){ref-type="fig"}A, Table [2](#T2){ref-type="table"}). No heterogeneity across studies was found (I^2^=0%, P~H~=0.723). Subgroup analysis by tumor type showed that high pretreatment plasma fibrinogen levels were associated with a worse OS in PCa (fixed effect model, pooled HR=2.26, 95% CI=1.47-3.48, P\<0.001), RCC (fixed effect model, pooled HR=2.13, 95% CI=1.75-2.61, P\<0.001) and UTUC (fixed effect model, pooled HR=2.34, 95% CI=1.81-3.02, P\<0.001) (Fig [2](#F2){ref-type="fig"}B). In subgroup analyses by race, high pretreatment fibrinogen levels predicted worse OS in both Asian (fixed effect model, pooled HR=2.07, 95% CI=1.73-2.49, P\<0.001) and Caucasian (random effect model, pooled HR=2.52, 95% CI=1.93-3.25, P\<0.001) populations (Fig [2](#F2){ref-type="fig"}C). Statistically significant pooled HR values were consistently calculated in subgroup analyses when stratified by different cutoff points. (Table [2](#T2){ref-type="table"}).

Cancer-specific survival
------------------------

Elevated pretreatment fibrinogen was associated with worse CSS in urological cancers (fixed effect model, pooled HR=2.67, 95%CI=2.23-3.19, P\<0.001) (Fig [3](#F3){ref-type="fig"}, Table [3](#T3){ref-type="table"}). No heterogeneity was observed among studies (I^2^=0%, P~H~=0.888). Subgroup analyses by tumor type showed that high pretreatment fibrinogen levels were associated with reduced CSS in PCa (fixed effect model, pooled HR=2.42, 95% CI=1.44-4.07, P=0.001), RCC (fixed effect model, pooled HR=2.99, 95% CI=2.29-3.89, P\<0.001) and UTUC (fixed effect model, pooled HR=2.43, 95% CI=1.84-3.20, P\<0.001) patients (Fig [3](#F3){ref-type="fig"}B, Table [3](#T3){ref-type="table"}). High pretreatment plasma fibrinogen level was also associated with worse CSS in Asian (fixed effect model, pooled HR=2.63, 95% CI=2.14-3.22, P\<0.001) and Caucasian (fixed effect model, pooled HR=2.83, 95% CI=1.92-4.17, P\<0.001) populations. This effect was greater in Caucasian than Asian patients (Fig [3](#F3){ref-type="fig"}C, Table [3](#T3){ref-type="table"}). Different cut-off points both showed prognostic value of plasma fibrinogen for CSS.

Publication bias
----------------

Publication bias in the included investigations was assessed using Begg\'s test and Egger\'s linear regression test. In Begg\'s test, P=0.213 for OS and P=0.064 for CSS. In Egger\'s test, P=0.119 for OS and P=0.111 for CSS. Thus, no significant publication bias was observed in our meta-analysis. The Egger\'s linear regression graph is shown in Figure [4](#F4){ref-type="fig"}.

Discussion
==========

Our meta-analysis included 6740 patients in 14 eligible studies of good quality as assessed by the NOS score system. Our findings suggest that pretreatment plasma fibrinogen levels can be used to predict survival outcomes in urological cancers. High pretreatment plasma fibrinogen levels predicted shorter OS and CSS in patients with RCC, PCa, or UTUC. In subgroup analyses, RCC had the highest HR value for CSS, while UTUC had the highest HR value for OS, indicating that pretreatment plasma fibrinogen had the best predictive value for CSS in RCC and OS in UTUC. The prognostic value of pretreatment fibrinogen was confirmed in all three urological cancer types despite different effect sizes. When stratified by race, pretreatment plasma fibrinogen had stronger predictive values for both OS and CSS in Caucasian patients than Asians.

While no bladder cancer studies met our inclusion criteria, the association between pretreatment plasma fibrinogen level and bladder cancer clinicopathological characteristics has been assessed. Liu, *et al.* reported that advanced stage (high grade or muscle-invasive) bladder urothelial carcinoma patients had higher plasma fibrinogen levels than those with early-stage (low grade or non-muscle-invasive) disease, and high plasma fibrinogen level (\>3.04g/L) was identified as an independent predictor of advanced-stage disease [@B14]. Another study also showed that fibrinogen level (cut-off value 3.17g/L) could aid in distinguishing between muscle-invasive and non-muscle-invasive bladder cancer (sensitivity 58%, specificity 58%, AUC 0.6) [@B15].

Negative associations between fibrinogen and tumor prognosis have been reported in multiple cancers, including lung [@B16], ovarian [@B17], cervical [@B18], hepatocellular [@B19], pancreatic [@B20], and colorectal cancer [@B21], [@B22]. However, the underlying biological mechanisms describing this relationship have not been fully elucidated. Fibrinogen appears to promote tumor proliferation, progression, and metastasis, and can be endogenously synthesized and secreted by cancer cells [@B2], [@B23]. Fibrinogen can stimulate cancer cell proliferation and angiogenesis by binding to transforming growth factor-β (TGF-β), vascular growth factor (VEGF), fibroblast growth factor-2 (FGF-2), and platelet-derived growth factor (PDGF) [@B2], [@B24]-[@B26]. Fibrinogen is also a critical determinant of tumor growth with plasminogen in the tumor microenvironment [@B27] and can increase the metastatic potential of malignant tumors. Joseph, *et al.* suggested that fibrinogen deficiency reduced the incidence of spontaneous metastasis in aggressive tumors via both hematogenous and lymphatic routes [@B28]. Another study indicated that formation of platelet-fibrin-tumor cell aggregates is related to tumor cell endothelial adhesion and metastatic potential, and that fibrinogen may facilitate metastasis by enhancing the sustained adherence and survival of circulating tumor cell emboli in the vasculature of target organs [@B29]. In addition, fibrinogen may protect tumor cells from natural killer cell cytotoxicity because of their strong adhesion to tumor cells, which facilitated the immuno-escape and accelerated the metastasis of tumor cells [@B30].

Despite advances in anti-cancer therapies, some patients still experience poor clinical outcomes due to low objective response rates, tumor local recurrence, and distal metastasis. Novel biomarkers are needed to identify these patients. Studies showed some inflammation response biomarkers, such as C-reactive protein, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR), were prognostic indicators of solid tumor outcomes [@B31], [@B32]. Plasma fibrinogen is associated with hemostasis maintenance and is a key factor in inflammation. Based on previous studies, our analysis revealed that plasma fibrinogen is a prognostic biomarker that could help identify high-risk urological cancer patients before treatment. Early identification of these patients and appropriate therapeutic decision-making could improve survival outcomes. The use of anticoagulants could diminish the risk of tumor thrombosis and hematogenous metastasis in patients with elevated plasma fibrinogen. Recombinant desulfatohirudin, a highly specific thrombin inhibitor, suppressed tumor metastasis in an animal model [@B33].

To our knowledge, this is the first meta-analysis to comprehensively assess the prognostic value of plasma fibrinogen in urological cancers. We found no significant heterogeneity or publication bias in our analysis. However, our study had certain limitations. First, the study by Niedworok, *et al.* [@B36] lacked multivariate analyses, so we used HRs from univariate analyses to calculate the pooled HR. Univariate analysis may overestimate effect sizes because of confounder bias. However, our meta-analysis did not show any notable difference in the pooled estimation when we excluded this study. Second, we estimated OS and CSS, but did not assess other survival outcomes, such as disease-free survival and progression-free survival. This was primarily due to a lack of data in the included articles. Third, our analysis included a small number of studies, and some cancer types, such as bladder cancer, were not included in the final analysis. Finally, because our meta-analysis was based on observational studies, we could not draw robust conclusions about how plasma fibrinogen level changes influence survival outcomes. Only the association between pretreatment plasma fibrinogen level and poor survival outcome could be deduced.

In conclusion, our meta-analysis was based on present studies and it revealed that high pretreatment plasma fibrinogen levels can predict worse OS and CSS in urological cancer patients. While further clinical studies are needed, our results suggest that pretreatment plasma fibrinogen might be an effective prognostic biomarker for such patients and could potentially influence decision-making during treatment.
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![**Meta-analysis of the association between pretreatment plasma fibrinogen and OS in urological cancers.** Forest plot of studies evaluating pooled HR for OS in urological cancers **A.** Forest plots of subgroup analyses by cancer type **B**. and race **C.** for OS.](jcav10p0479g002){#F2}

![**Meta-analysis of the association between pretreatment plasma fibrinogen and CSS in urological cancers.** Forest plot of studies evaluating pooled HR for CSS in urological cancers **A**. Forest plots of subgroup analyses by cancer type **B**. and race **C**. for CSS.](jcav10p0479g003){#F3}

![**Egger\'s linear regression test.** Egger\'s publication bias plots for OS **A.** and CSS **B.**](jcav10p0479g004){#F4}

###### 

Characteristics of all 14 studies included in the meta-analysis

  Author      Year   Country         Tumor site   N of patients   Age (years)             Gender (M/F)   Cut-off value (mg/dL)   Follow-up (Months)           HR provided from   Outcome      NOS score
  ----------- ------ --------------- ------------ --------------- ----------------------- -------------- ----------------------- ---------------------------- ------------------ ------------ -----------
  Thurner     2015   Austria[@B7]    PCa          268             Mean: 66.9±7.5          268/0          530                     88(83.3-92.7)                MV/UV              CSS,OS,DFS   8☆
  Wang        2016   China[@B34]     PCa          290             Mean: 75 (67-79)        290/0          322.5                   37(24.0-50.3)                MV/UV              CSS,OS,PFS   6☆
  Du          2013   China[@B6]      RCC          286             Median: 55.72 (28-77)   185/101        300/400                 died: 34.6 survivors: 94.5   MV/UV              OS,DFS       7☆
  Pichler     2013   Austria[@B35]   RCC          994             Mean: 63.2±11.9         599/395        466                     48.1(0-132)                  MV/UV              CSS,OS       7☆
  Erdem       2014   Turkey[@B11]    RCC          156             Mean: 58.66±11.31       91/37          343                     36.5(1-88)                   MV/UV              CSS,OS,DFS   8☆
  Niedworok   2015   Germany[@B36]   RCC          98              Mean: 64.6(18-88)       61/37          281                     36(20-122)                   UV                 OS,DFS       6☆
  Sasaki      2015   Japan[@B37]     RCC          126             Median: 67(37-86)       84/42          399                     30.8(2-135)                  MV/UV              OS           7☆
  Lee         2016   Korea[@B10]     RCC          1511            Median: 57.6(19-86)     1077/434       328                     36(24-57)                    MV/UV              CSS,OS,PFS   7☆
  Obata       2016   Japan[@B38]     RCC          601             Median 58(50-67)        467/134        420                     74(47-107)                   MV/UV              CSS,DFS      8☆
  Peng        2017   China[@B39]     RCC          1360            Median 55(46-65)        952/408        387                     67(36-74)                    MV/UV              CSS,PFS      7☆
  Pichler     2014   Austria[@B40]   UTUC         167             Mean: 69.3±10.3         122/80         370                     28                           MV/UV              CSS,OS       8☆
  Tanaka      2013   Japan[@B8]      UTUC         218             Mean: 69(38-92)         160/58         450                     38(3-187)                    MV/UV              CSS          8☆
  Zhang       2016   China[@B41]     UTUC         184             Median: 70(61-75)       84/100         354                     78(34-92)                    MV/UV              CSS,OS       8☆
  Huang       2016   China[@B42]     UTUC         481             Mean: 65.8±11.1         311/170        422                     40(24-64)                    MV/UV              CSS,OS       8☆

**PCa**: prostate cancer, **RCC:** renal cell carcinoma, **UTUC:** upper tract urothelial carcinoma, **MV:** multivariate, UV: univariate, **OS**: overall survival, **CSS**: cancer-specific survival, **DFS**: disease-free survival, **PFS**: progression-free survival

###### 

HR values for OS according to subgroup analysis

  Subgroup        No. studies   No. patients   Fixed-effects model   Heterogeneity         
  --------------- ------------- -------------- --------------------- --------------- ----- -------
  Tumor Site                                                                               
  *PCa*           2             558            2.26 (1.47-3.48)      \<0.001         2.7   0.311
  *RCC*           6             3171           2.13 (1.75-2.61)      \<0.001         5.1   0.384
  *UTUC*          3             832            2.34 (1.81-3.02)      \<0.001         0     0.811
  Ethnicity                                                                                
  *Asian*         6             2878           2.07 (1.73-2.49)      \<0.001         0     0.490
  *Caucasian*     5             1683           2.52 (1.95-3.25)      \<0.001         0     0.893
  Cut-off value                                                                            
  *\<350mg/dl*    5             2055           1.91(1.52-2.40)       \<0.001         0     0.858
  *≥350mg/dl*     6             2506           2.46(2.03-2.98)       \<0.001         0     0.707
  Overall         11            4561           2.21(1.91-2.57)       \<0.001         0     0.723

OS: overall survival, HR: hazard ratio, CI: confidence interval, PH: P for heterogeneity, PCa: prostate cancer, RCC: renal cell carcinoma, UTUC: upper tract urothelial carcinoma.

###### 

HR values for CSS according to subgroup analyses.

  Subgroup        No. studies   No. patients   Fixed-effects model   Heterogeneity       
  --------------- ------------- -------------- --------------------- --------------- --- -------
  Tumor Site                                                                             
  *PCa*           2             558            2.42 (1.44-4.07)      0.001           0   0.425
  *RCC*           6             4720           2.99 (2.29-3.89)      \<0.001         0   0.716
  *UTUC*          4             1050           2.43 (1.84-3.20)      \<0.001         0   0.807
  Ethnicity                                                                              
  *Asian*         7             4645           2.63 (2.14-3.22)      \<0.001         0   0.600
  *Caucasian*     5             1683           2.83 (1.92-4.17)      \<0.001         0   0.894
  Cut-off value                                                                          
  *\<350mg/dl*    4             2055           2.65(1.74-4.03)       \<0.001         0   0.743
  *≥350mg/dl*     8             4273           2.67(2.19-3.26)       \<0.001         0   0.716
  Overall         12            6328           2.67 (2.23-3.19)      \<0.001         0   0.888

CSS: cancer-specific survival, HR: hazard ratio, CI: confidence interval, *PH* : P for heterogeneity, PCa: prostate cancer, RCC: renal cell carcinoma, UTUC: upper tract urothelial carcinoma.
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